Showing 2551-2560 of 5693 results for "".
- Regenxbio to Receive $80 Million Milestone Payment from Novartishttps://modernod.com/news/regenxbio-to-receive-80-million-milestone-payment-from-novartis/2478475/Regenxbio announced that it will receive a milestone payment of $80 million from Novartis based upon the achievement of $1 billion in cumulative net sales of Zolgensma. Regenxbio expects to recognize this revenue in the third quarter of 2020. “Zolgensma is a transformative, one-time
- Norlase Announces FDA Clearance and US Launch of New LION Laser Systemhttps://modernod.com/news/norlase-announces-fda-clearance-and-u-s-launch-of-new-lion-laser-system/2478470/Norlase announced the 510(k) clearance from the FDA and the immediate commercial launch of Norlase LION, a green laser photocoagulator fully-integrated into a Keeler indirect ophthalmoscope. Unlike other laser indirect ophthalmoscopes that require a fiber optic connection to a laser source
- Bausch + Lomb Introduces SimplifEYE IOL Delivery System for Envista Toric and Monofocal Preloaded IOLshttps://modernod.com/news/bausch-lomb-introduces-simplifeye-iol-delivery-system-for-envista-toric-and-monofocal-preloaded-iols/2478461/Bausch + Lomb announced the introduction of the SimplifEYE IOL delivery system, which is available exclusively for the enVista MX60PL and the enVista toric MX60PT, the first preloaded toric IOL available in the United States. “Surgeons recognize that using a preloaded IOL system can stream
- Nicox Selects Development Candidate in a New Class of NO-Mediated IOP Lowering Agentshttps://modernod.com/news/nicox-selects-development-candidate-in-a-new-class-of-no-mediated-iop-lowering-agents/2478452/Nicox SA announced that it has selected a new development candidate, NCX 1728, from its proprietary research program focused on nitric oxide (NO)-mediated IOP lowering agents. An analog of this molecule has demonstrated positive results in ocular hypertensive
- STRAP Technologies Announces Device to Aid the Visually Impairedhttps://modernod.com/news/strap-technologies-announces-device-to-aid-the-visually-impaired/2478430/STRAP Technologies announced the creation of a hands-free device designed to be worn by the visually impaired to allow for more independence and mobility. STRAP is a wearable, hands-free device with an array of sensors that work by sending real-time information that detect obstacles at the
- Coherent Ships 5,000th OEM ExciStar Devicehttps://modernod.com/news/coherent-ships-5000th-oem-excistar-device/2478427/Coherent recently delivered the 5,000th OEM ExciStar laser for refractive corneal surgery. “The longevity of the laser components and the excellent pulse stability at the ultra-short 193 nm laser wavelength have made the ExciStar family the ideal ablation source for ever faster and m
- Pfizer CEO Says Late November is Earliest Possible Filing Date for COVID-19 Vaccine in UShttps://modernod.com/news/pfizer-ceo-says-late-november-is-earliest-possible-filing-date-for-covid-19-vaccine-in-us/2478428/Pfizer CEO Albert Bourla said that the earliest the company will apply for FDA emergency-use authorization (EUA) for its COVID-19 vaccine program would be shortly after a key safety milestone is met, which is currently expected to be in the third week of November. “As we get closer to an im
- CVS, Walgreens Make Deal With Trump Admin to Quickly Distribute COVID-19 Vaccines to Nursing Homeshttps://modernod.com/news/cvs-walgreens-make-deal-with-trump-admin-to-quickly-distribute-covid-19-vaccines-to-nursing-homes/2478429/Retail pharmacy chains CVS Health and Walgreens reached a deal with the Trump administration to quickly provide and administer COVID-19 vaccines directly to nursing homes with no out-of-pocket costs, according to a FierceHealthcare
- BVI Acquires Benz Research & Development, Strengthening IOL Design, Production and Sales Capabilitieshttps://modernod.com/news/bvi-acquires-benz-research-development-strengthening-iol-design-production-and-sales-capabilities/2478419/BVI announced its recent completion of the acquisition of Benz Research & Development and its customized contact lens subsidiary, SpecialEyes, both based in Sarasota, Florida. Terms of the deal were not disclosed. The Benz portfolio of performanc
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho